Kenneth Bender

Most dermatologists in the United Kingdom choose phototherapy first when treating adult patients with recalcitrant moderate-to-severe atopic eczema/dermatitis (AD).

The first study to associate genetic variances linked to skin barrier deficiencies and immune response in atopic eczema/dermatitis with the responses to treatment over several years has moved the field closer to individualizing precision therapies for the condition.

An over-the-counter (OTC) treatment was considered superior to both the corticosteroid and an emollient cream in improving skin hydration.

Not all herbal treatments were found to successfully treat moderate-to-severe eczema as previously thought.

Previous research showed probiotics given to pregnant women during certain stages of pregnancy and post delivery reduced the likelihood of atopic dermatitis in their children. Recently published reports; however, may not agree.

Children with atopic dermatitis (AD) were reported to have a greater risk for developing contact dermatitis from some common ingredients of topical products than those with a history of contact dermatitis but no AD, in a recent comparison of patch testing responses in both groups.

Individuals with atopic asthma were recently found to have a distinctive bronchial bacterial microbiome that not only differs from those without asthma, but between asthmatics with phenotypes more responsive or resistant to inhaled corticosteroids.

An inhaled corticosteroid and long-acting beta2-agonist bronchodilator combination was found more beneficial for patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome (ACOS) than for those with COPD alone.

A recent survey of asthma treatment in intensive care units of children's hospitals in the US reveals wide variability between institutions in both medication and ventilation interventions.

In a recent survey of pediatric dermatologists, cyclosporine (Neoral/ Novartis, SandIMMUNE/ Sandoz, others) was the most common choice of systemic agent to treat severe pediatric atopic dermatitis (AD), followed by methotrexate (Trexall, Teva, others).

Patients who discontinued long-term treatment with omalizumab (Xolair/Genentech and Novartis) were more likely to experience an episode of severe asthma exacerbation during a one-year monitoring period than those who continued the treatment, in a recent study to determine whether therapeutic effect persists after discontinuation.

Multiple measurements of skin integrity and function were applied to distinguish between the effects of topical emollient products in a recent study. Two popular products in the UK were determined to transiently improve the skin barrier that is thought to be defective in atopic dermatitis (AD), and another product was confirmed to be damaging.

Researchers report that atopic dermatitis (AD) is associated with increased risk of ADHD in adults and children. Patients with more severe AD were at even higher risk.

The aspects of atopic dermatitis that most concern patients and their caregivers are not well represented among the areas that are studied in clinical research.

A modified Goeckerman regimen was associated with significant improvement of symptoms in patients with chronic, severe atopic dermatitis.

One year after the November 2015 FDA approval of mepolizumab (Nucala, GlaxoSmithKline) to treat severe asthma with eosinophilic phenotype, a review considers how initial studies missed its effectiveness, the subsequent evidence that supported its utility, and possible future applications.

Proactive administration of topical corticosteroid was found to reduce allergen sensitization in patients with atopic dermatitis (AD) as well as the periodic exacerbation of pruritic eczema.

Approved by the FDA to treat plaque psoriasis, psoriatic arthritis, and active Crohn's disease, ustekinumab appeared to benefit patients with severe atopic dermatitis (AD) in a small study seeking to correlate its immunologic effects with clinical efficacy.

The technologies of texting, phone apps, and social media are being applied to asthma self-management programs for adolescents to enhance adherence to medication and effective response to symptoms.

According to a recently published review, development is proceeding on vaccines that hope to prevent or mitigate asthma, with several approaches advancing to clinical trial.

Atopic dermatitis comes with added infection risk.

Dermatitis researchers use far too many instruments in measuring symptoms of skin ailments, a study found. Symptoms of atopic ezcema/dermatitis (AD) were found in a systematic review of randomized controlled trials (RCTs) to be most often characterized from composite measures rather than stand-alone symptom severity rating instruments, and thirty different instruments were found to have been used across 378 trials.

Severe atopic dermatitis (AD) symptoms of shorter duration were more likely to improve in allergen sensitized patients receiving desensitizing immunotherapy, than severe symptoms of longer duration or more moderate symptoms, according to a new observational cohort study.

Severe atopic dermatitis (AD) symptoms of shorter duration were more likely to improve in allergen sensitized patients receiving desensitizing immunotherapy, than severe symptoms of longer duration or more moderate symptoms, according to a new observational cohort study.

The issue of when to use eczema and when atopic dermatitis has thrown a wrench into data-mining machinations.

Childhood atopic dermatitis (AD) usually resolves before adulthood, a meta-analysis of cases showed. Those patients who did see their AD persist were more likely to be female, to have been older at onset, and to have relatively severe AD.

An early clinical trial of a topical preparation of tofacitinib, a janus kinase (JAK) inhibitor, demonstrated that it improved symptoms of atopic dermatitis (AD) and was well tolerated.

An increasing number of studies of treatment effectiveness for atopic dermatitis (AD) are measuring changes in quality of life (QOL) as well as in symptoms.

Topical corticosteroid worked as well as bleach in transforming the microbiota of affected skin to that of healthy skin, an NYU study found.

Phototherapy can be effective in treating AD but not all patients have access to the therapy, a study found.